2,2-二甲基-4-苯基-丁酸酰胺 | 861053-17-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,2-二甲基-4-苯基-丁酸酰胺
• 英文名称: 2,2-dimethyl-4-phenyl-butyric acid amide
• 英文别名: 2,2-Dimethyl-4-phenyl-buttersaeure-amid；2,2-Dimethyl-4-phenylbutanamide
• CAS: 861053-17-0
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: UXQWANBEXSAVDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,2-二甲基-4-苯基-丁酸酰胺 在 氢氧化钾 作用下， 生成 2,2-二甲基-4-苯基丁酸
  参考文献：
  名称：

  Ramart; Hoch, Bulletin de la Societe Chimique de France, 1938, vol. <5> 5, p. 848,860

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium amide 、 甲苯 作用下， 生成 2,2-二甲基-4-苯基-丁酸酰胺
  参考文献：
  名称：

  Ramart; Hoch, Bulletin de la Societe Chimique de France, 1938, vol. <5> 5, p. 848,860

  摘要：

  DOI：

文献信息

• [EN] TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS<br/>[FR] COMPOSÉS TRIAZOLONE UTILISÉS COMME INHIBITEURS DE LA MPGES-1
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2013186692A1

  公开（公告）日：2013-12-19

  The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

  本公开涉及式(I)的化合物及其药用盐，作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此在治疗来自各种疾病或病况的疼痛和/或炎症方面具有用处，如哮喘、骨关节炎、类风湿关节炎、急性或慢性疼痛和神经退行性疾病。
• Fluoroamide-Directed Regiodivergent C-Alkylation of Nitroalkanes
  作者：Zhibin Du、Shiwen Liu、Yuke Li、Junjie Peng、Yanji Sun、Yanshan Song、Yuxuan Liu、Xiaojun Zeng

  DOI：10.1021/acs.orglett.3c01297

  日期：2023.6.30

  Herein, by exploiting different activation modes of fluoroamides, we achieved α- and δ-C(sp3)–H alkylation of nitroalkanes with switchable regioselectivity. Cu catalysis enabled the interception of a distal C-centered radical by a N-centered radical to couple nitroalkanes and unactivated δ-C–H bonds. In addition, imines generated in situ by fluoroamides were trapped by nitroalkanes to realize the α-C–H

  在此，通过利用氟酰胺的不同活化模式，我们实现了具有可切换区域选择性的硝基烷烃的α-和δ-C(sp 3 )–H烷基化。Cu 催化作用使得以 N 为中心的自由基拦截远端以 C 为中心的自由基，从而偶联硝基烷烃和未活化的 δ-C-H 键。此外，氟酰胺原位生成的亚胺被硝基烷烃捕获，实现酰胺的α-C-H烷基化。这两种可扩展的协议都具有广泛的底物范围和良好的官能团耐受性。
• TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
  申请人：Glenmark Pharmaceuticals S.A.

  公开号：EP2718284A1

  公开（公告）日：2014-04-16
• [EN] ELEVATION OF HDL CHOLESTEROL BY 4-[(AMINOTHIOXOMETHYL) -HYDRAZONO] -N-(SUBSTITUTED) -4-ARYLBUTANAMIDES<br/>[FR] AUGMENTATION DU CHOLESTEROL LPHD AU MOYEN DE 4-[(AMINOTHIOXOMETHYL)-HYDRAZONO]-N-(SUBSTITUES)-4-ARYLBUTANAMIDES
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：WO1999025682A1

  公开（公告）日：1999-05-27

  (EN) Compounds of this invention increase plasma levels of high density lipoprotein or HDL, the 'good' cholesterol and as such may be useful for treating diseases such as atherosclerosis. These compounds are represented by formula (A), wherein: R1, R2, and R3 are independently hydrogen, C1-C6 alkyl, phenyl or -(CH2)1-6 phenyl where phenyl is optionally substituted by halogen, cyano, nitro, C1-C6 alkyl, C1-C6 alkoxy, trifluoromethyl, C1-C6 alkoxycarbonyl, -CO2H or OH; R4 and R5 are independently hydrogen, C1-C10 alkyl, C3-C8 cycloalkyl, -(CH2)0-6Ar1 where Ar1 is phenyl, naphthyl, furanyl, pyridinyl or thenyl and Ar1 can be optionally substituted by halogen, cyano, nitro, C1-C6 alkyl, phenyl, C1-C6 alkoxy, phenoxy, trifluoromethyl, C1-C6 alkoxycarbonyl, -CO2H or OH, or R4 and R5 together with the nitrogen to which R4 and R5 are attached from a ring containing 4-7 carbon atoms; and Ar is phenyl, naphthyl, furanyl, pyridinyl or thienyl which may be optionally substituted by halogen, cyano, nitro, C1-C6 alkyl, C3-C6 cycloalkyl, phenyl, C1-C6 alkoxy, phenoxy, trifluoromethyl, C1-C6 alkoxycarbonyl, -CO2H or OH.(FR) L'invention concerne des composés qui augmentent le taux de plasma de lipoprotéine de haute densité ou LPHD, le 'bon' cholestérol, et qui peuvent ainsi être utilisés pour le traitement de maladies telles que l'athérosclérose. Ces composés sont représentés par la formule (A), dans laquelle R1, R2 et R3 représentent indépendamment hydrogène, alkyle C1-C6, phényle ou -(CH2)1-6phényle où phényle est éventuellement substitué par halogène, cyano, nitro, alkyle C1-C6, alcoxy C1-C6, trifluorométhyle, alcoxycarbonyle C1-C6, -CO2H ou OH; R4 et R5 représentent indépendamment hydrogène, alkyle C1-C10, cycloalkyle C3-C8, -(CH2)0-6Ar1 où Ar1 représente phényle, naphtyle, furanyle, pyridinyle ou thényle et Ar1 peut être éventuellement substitué par halogène, cyano, nitro, alkyle C1-C6, phényle, alcoxy C1-C6, phénoxy, trifluorométhyle, alcoxycarbonyle C1-C6, -CO2H ou OH, ou R4 et R5 forment avec l'azote auquel ils sont attachés un noyau de 4-7 atomes de carbone; et Ar représente phényle, naphtyle, furanyle, pyridinyle ou thiényle qui peuvent être éventuellement substitués par halogène, cyano, nitro, alkyle C1-C6, cycloalkyle C3-C6, phényle, alcoxy C1-C6, phénoxy, trifluorométhyle, alcoxycarbonyle C1-C6, -CO2H ou OH.
• [EN] BIFUNCTIONAL CATALYSTS<br/>[FR] CATALYSEURS BIFONCTIONNELS
  申请人：UNIV DURHAM

  公开号：WO2004113351A2

  公开（公告）日：2004-12-29

  Bifunctional Lewis acid - Lewis base catalyst of Formula (I): wherein O is a C2-60 optionally heteroatom containing substituted or unsubstituted hydrocarbon scaffold comprising pendant or integral bifunctional groups LA and LB wherein LA is a pendant or integral boron or silicon Lewis acid group and LB is a pendant or integral phosphorus or nitrogen Lewis base group and its salts, N-fanctionalised derivatives, dimer or oligomer thereof; processes for the preparation thereof; novel compounds and novel intermediates; a composition comprising a catalyst or compound of the invention; a kit comprising one or more catalysts; the use thereof as catalysts in selective transformations, kits therefor and processes for selective transformation reactions catalysed thereby; screening methods to identify catalysts for specific transformations; and kits therefor.